cedUnrers
Guest
Joined: 01 October 2003
Online Status: Online
Posts: 157642
|
| Posted: 30 June 2011 at 3:26am | IP Logged
|
|
|
A US medical journal on Tuesday published a scathing critique of industry-funded studies on spine research, alleging that they failed to report adverse events to the journals that publish them.
The review study came days after the Senate Finance Committee launched an inquiry into whether doctors being paid by device giant Medtronic failed to report serious side effects from the bone-growth agent Infuse in clinical studies.
The product was introduced in 2002 to help bones heal after spinal surgery and has been used in about 500,000 patients. Since its arrival on the market, it has also been linked to some cases of cancer, male sterility, throat swelling and leg pain.
A Loyola University spokesman told AFP that some doctors in the spinal community believe that a "small number, fewer than five" fatalities may have resulted from its use, though no published data points to any deaths.
The review article co-authored by three US-based doctors in The Spine Journal says that in 13 trials involving 780 patients, "industry-funded researchers did not report a single adverse advent involving Medtronic's Infuse Bone Graft."
Meanwhile, the authors of "nearly all the trials had financial ties with the manufacturer, with investigators earning as much as $26 million per study," the journal reported.
The product brings in about $900 million in annual revenues for Medtronic, according to US media.,
|
Active Topics 
Memberlist 
Search 
Help
Register 
Login
Full Tilt Forum : General Discussion
Topic: US bone-growth studies under fire for all
